Processa Pharmaceuticals doses first subject in Phase II breast cancer trial
The goal is to assess the safety, efficacy and determine optimal dosing regimens of NGC-Cap.
The goal is to assess the safety, efficacy and determine optimal dosing regimens of NGC-Cap.
The primary endpoint results from the trial are expected by the end of the year and will be used to support an FDA approval for the OCT B-Series device.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Microbot shifts pivotal trial up a gear with completion expected ahead of schedule
Moderna blamed after children offered £1,500 to take part in Covid-19 trial
Wesper sleep platform reduces nerve stimulation titration time by 45%
Alio starts trial to expand label for remote monitoring device